- Full-Year Global Net Revenues from the Hematologic Oncology Portfolio Were $7.228 Billion, an Increase of 8.7 Percent on a Reported Basis, or 8.3 Percent on an Operational Basis; Global Imbruvica. a   Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. Note: "Comparable Operational" comparisons include full-quarter current year and prior year results for Allergan, which was acquired on May 8, 2020, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates. "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. The adjusted tax rate for the full-year 2021 was 12.5 percent, as detailed below: Acquisition and integration costs reflect transaction and financing costs, compensation expense and other integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. AbbVie received information requests from the FDA for an updated assessment of the benefit-risk profile for Rinvoq in both indications. The approval is supported by two pivotal Phase 3 studies that demonstrated Vuity works in as early as 15 minutes and lasts for up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision. Comparable store sales for the three months ended Dec. 25, 2021 increased 10.5%. The approval includes two dose strengths (15 mg and 30 mg, once daily) and is supported by efficacy and safety data from one of the largest registrational Phase 3 programs for AD with more than 2,500 patients evaluated across three studies. At the 2021 American Headache Society (AHS) Annual Scientific Meeting, AbbVie presented a total of 23 abstracts, including four podium presentations, from a broad range of studies across AbbVie's . Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. The information in the press releases on these pages was factually accurate on the date of publication. The company's stock fell 6 percent following an earnings report that included a $2.2 billion charge related to the opioid deal. AbbVie Financial Statements 2009-2021 | ABBV | MacroTrends Commodities Exchange Rates Interest Rates Economy AbbVie Financial Statements 2009-2021 | ABBV Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics Income Statement Balance Sheet Cash Flow Statement Key Financial Ratios View Annual Reports On October 30, 2020, AbbVie announced that its board of directors declared an increase in the quarterly cash dividend from $1.18 per share to $1.30 per share beginning with the dividend payable on February 16, 2021 to stockholders of record as of January 15, 2021. AbbVie undertakes no obligation to release publicly any revisions to forward . View our social media channel guidelines », AbbVie.com The company's 2022 adjusted diluted EPS guidance excludes $4.74 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items. All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. AbbVie anticipates a regulatory decision in late 3Q 2021. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. The adjusted gross margin ratio was 83.6 percent. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. In June 2021, the US Senate Finance Committee, under . Quarter and Twelve Months Ended December 31, 2021 and 2020, (Unaudited) (In millions, except per share data), Acquired in-process research and development, Earnings (loss) before income tax expense, Net earnings attributable to noncontrolling interest. The adjusted tax rate was 12.3 percent. Sustainability at ABB CEO message. Humira, produced by AbbVie for a variety of conditions including rheumatoid arthritis, is the highest-grossing drug of all time with $21 billion in annual global sales as of 2021. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. • Working with the cross functional project team on the design, development and validation of FP&A . AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite. The approval is supported by two Phase 3 clinical studies where Skyrizi demonstrated significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo. On a GAAP basis, the gross margin ratio in the first quarter was 67.6 percent. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A, AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call, AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference, AbbVie Reports Third-Quarter 2022 Financial Results, AbbVie to Present at the Morgan Stanley Healthcare Conference, AbbVie Reports Second-Quarter 2022 Financial Results, AbbVie to Host Second-Quarter 2022 Earnings Conference Call, AbbVie Reports First-Quarter 2022 Financial Results, AbbVie to Host First-Quarter 2022 Earnings Conference Call, AbbVie to Present at the Cowen 42nd Annual Health Care Conference. Financial - Dividend Highlight. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. This milestone marked the third FDA-approved indication for Rinvoq. Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. 3. | AbbVie Reports First-Quarter 2021 Financial Results, Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A, Diluted earnings per share attributable to, http://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2021-financial-results-301281124.html, Global net revenues from the immunology portfolio were, Global net revenues from the hematologic oncology portfolio were, Global net revenues from the aesthetics portfolio were, Global net revenues from the neuroscience portfolio were, Global Botox Therapeutic net revenues were. The adjusted tax rate for the fourth quarter of 2020 was 11.6 percent, as detailed below: Acquisition and integration costs reflect Allergan integration costs, Soliton acquisition costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition partially offset by a recovery of certain Allergan acquisition-related regulatory fees. Specified items impacted results as follows: Change in fair value of contingent consideration. The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . | Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of FDA priority review vouchers from third parties. Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A. Carbon footprint. AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our first-quarter performance. Weighted-average diluted shares outstanding includes the effect of dilutive securities. AbbVie announced the FDA approved Vuity (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly half of the adult. (Unaudited) (In millions, except per share data), Acquired in-process research and development, Net earnings attributable to noncontrolling interest. Pfizer said in its third-quarter report that it expects revenue this year of between $99.5 billion and $102 billion, compared to $81.3 billion last year. The adjusted tax rate for the fourth quarter of 2021 was 12.5 percent, as detailed below: a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs reflect integration costs and amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. AbbVie expects to deliver adjusted diluted EPS for the full-year 2022 of $14.00 to $14.20. Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. At the American College of Rheumatology's (ACR) annual meeting, AbbVie shared 38 abstracts from across its rheumatology portfolio that underscored AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases. The adjusted tax rate was 12.5 percent. View AbbVie's annual reports on Form 10-K and proxy statements. The adjusted tax rate for the full-year 2020 was 11.2 percent, as detailed below: Subscribe for email alerts AbbVie announced that the U.S. Food and Drug Administration (FDA) approved Rinvoq for the treatment of moderate to severe atopic dermatitis (AD) in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting PRESS RELEASE PR Newswire Nov. 8, 2021, 08:30 AM 1. The submission is supported by three pivotal Phase 3 studies in which Skyrizi demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy. BOTOX Therapeutic at AbbVie. AbbVie is raising its GAAP diluted EPS guidance for the full-year 2021 from $6.69 to $6.89 to $7.27 to $7.47. Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. AbbVie expects to deliver adjusted diluted EPS for the full-year 2021 of $12.32 to $12.52. At the American Academy of Ophthalmology Annual Meeting (AAO), AbbVie presented new data from its leading eye care portfolio. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of FDA priority review vouchers from third parties. Historically reported Allergan revenues also exclude Zenpep and Viokace product revenues, which were both divested as part of the acquisition, as well as specified items. View SEC filings (including Annual 10-K, Quarterly, Current report 8-k, Proxy, Section 16 and Registration Statements and other filings) from 1994 to present. Alumnae/i Giving. Reflects profit sharing for Imbruvica international revenues. The submission is supported by three pivotal Phase 3 studies in which Skyrizi demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy. 2021 - 2021 less than a year . On a GAAP basis, the tax rate in the quarter was 8.1 percent. AbbVie announced the FDA approved Vuity (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. The adjusted SG&A expense was 21.2 percent of net revenues. "Comparable Operational" comparisons include full-period current year and prior year results for Allergan products, as if the acquisition closed on January 1, 2019, and are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. May 2020 - Oct 20206 months. U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe CD and full results from the study will be presented at a future medical meeting and submitted for publication in a peer-reviewed journal. Financial - Income Highlight. Back Submit. -Managed weekly newsletter and . An archived edition of the call will be available after 11:00 a.m. Central time. AbbVie announced that it has extended its preclinical oncology research collaboration agreement with the. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without . Annual Report for 2021-22. Cookie Settings. b   All historically reported Allergan revenues have been recast to conform to AbbVie's revenue recognition accounting policies and reporting conventions for certain rebates and discounts. 2021, AbbVie announced that its board of directors declared an increase in the quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to stockholders of record as of January 14, 2022. . AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. The NDA is supported by data from a clinical program evaluating the efficacy, safety and tolerability of orally administered atogepant in nearly 2,500 patients who experience 4-14 migraine days per month, including data from the pivotal Phase 3 ADVANCE study in which all active treatment arms of atogepant met their primary endpoint and the 30 and 60 mg doses met all six secondary endpoints with statistical significance. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT . NORTH CHICAGO, Ill. , July 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022 , before the market opens. AbbVie . 2. President's Club 2021 . Fiscal year is January-December. AbbVie announced the FDA approved Rinvoq (15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call NORTH CHICAGO, Ill. , Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023 , before the market opens. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. . Other primarily includes COVID-19 related expenses, restructuring charges associated with streamlining global operations and tax related items, offset by milestone revenue under an existing collaboration agreement. The company's 2021 financial guidance is also being provided on both a reported and a non-GAAP basis. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. AbbVie Reports First-Quarter 2021 Financial Results117.1 KB - Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95 - Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis; Adjusted Net Revenues Were $12.935 Billion Vuity is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects nearly half of the U.S. adult population. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. Financial results for 2021 and 2020 are presented on both a reported and a non-GAAP basis. Highlights included new efficacy data on Rinvoq in people with active PsA and axial involvement, new long-term analysis evaluating the sustainability of response to Rinvoq among patients with RA as well as efficacy and safety data from the KEEPsAKE 1 and KEEPsAKE 2 trials evaluating Skyrizi in adults with PsA treated through 24 weeks. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Richard A. Gonzalez , chairman and chief executive officer, will present at 5:00 p.m. CT . AbbVie is issuing its GAAP diluted EPS guidance for the full-year 2022 of $9.26 to $9.46. On a GAAP basis, the operating margin in the first quarter was 31.5 percent. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram. AbbVie; ADP; Bank of America; Buchanan, Ingersoll and Rooney; CBRE; Cento Amici; ConnectOne Bank; CJ Devine Charitable Trust; Elizabeth Johns Bridals; . AbbVie announced that the FDA extended the review period for the supplemental New Drug Applications (sNDA) for Rinvoq in the treatment of adult patients with active PsA as well as in the treatment of adults and adolescents with moderate to severe atopic dermatitis (AD). On a GAAP basis, net interest expense was. Actual results may differ from those indicated as a result of various important factors, including those . AbbVie expects to deliver adjusted diluted EPS for the full-year 2022 of $14.00 to $14.20. AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. On a GAAP basis, the tax rate in the quarter was 5.3 percent. Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. Credit: AbbVie Inc. AbbVie has reported net revenues of nearly $56.2bn for the full year 2021 on a GAAP Basis, representing a rise of 22.7% compared to $45.8bn for the full year 2020. The adjusted SG&A expense was 22.2 percent of net revenues. . 1 AbbVie charges approximately $77,000 for a year's supply of Humira—470% more than when the drug was launched in 2003. The adjusted tax rate for the full-year 2021 was 12.5 percent, as detailed below: Acquisition and integration costs reflect transaction and financing costs, compensation expense and other integration costs as well as amortization of the acquisition date fair value step-up for inventory related to the Allergan acquisition. Sustainability at ABB Approach to reporting. Lemzoparlimab is being developed through a collaboration with AbbVie and I-Mab. Milestones and other R&D expenses include milestone payments for previously announced collaborations and the purchase of an FDA priority review voucher from a third party. • Led Pre and Post Launch global primary research, secondary analysis, and competitive . AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's stock price has collected -3.29% of loss in the last five trading sessions. At the American College of Rheumatology's (ACR) annual meeting, AbbVie shared 38 abstracts from across its rheumatology portfolio that underscored AbbVie's commitment to advancing its portfolio of medicines to help more people living with rheumatic diseases. AbbVie announced the launch of Refresh Digital lubricant eye drops, a new lubricant eye drop formulated to specifically relieve dryness and irritation that may occur from prolonged screen time. At the American Society for Dermatologic Surgery meeting, Allergan Aesthetics presented 6 abstracts from its leading portfolio of aesthetic treatments and products, which highlighted its approach to innovative science and commitment to bring new and impactful treatments to customers and patients globally. On a GAAP basis, research and development expense was 12.3 percent of net revenues. Weighted-average diluted shares outstanding includes the effect of dilutive securities. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.37 to $12.57 to $12.52 to $12.62. - Announces 2021 Dividend Increase of 10.2 Percent, Beginning with Dividend Payable in February 2021. - Reports Full-Year Diluted EPS of $6.45 on a GAAP Basis, an Increase of 137.1 Percent; Adjusted Diluted EPS of $12.70, an Increase of 20.3 Percent, - Delivers Full-Year Net Revenues of $56.197 Billion on a GAAP Basis, an Increase of 22.7 Percent; Adjusted Net Revenues Were $56.122 Billion, - Full-Year Global Net Revenues from the Immunology Portfolio Were $25.284 Billion, an Increase of 14.1 Percent on a Reported Basis, or 13.5 Percent on an Operational Basis; U.S. Humira Net Revenues Were $17.330 Billion, an Increase of 7.6 Percent; Internationally, Humira Net Revenues Were $3.364 Billion, a Decrease of 9.6 Percent on a Reported Basis, or 12.8 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $2.939 Billion; Global Rinvoq Net Revenues Were $1.651 Billion, - Full-Year Global Net Revenues from the Hematologic Oncology Portfolio Were $7.228 Billion, an Increase of 8.7 Percent on a Reported Basis, or 8.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $5.408 Billion, an Increase of 1.8 Percent, with U.S. Net Revenues of $4.321 Billion and International Profit Sharing of $1.087 Billion; Global Venclexta Net Revenues Were $1.820 Billion, - Full-Year Global Net Revenues from the Neuroscience Portfolio Were $5.927 Billion; Global Botox Therapeutic Net Revenues Were $2.451 Billion; Vraylar Net Revenues Were $1.728 Billion, - Full-Year Global Net Revenues from the Aesthetics Portfolio Were $5.233 Billion; Global Botox Cosmetic Net Revenues Were $2.232 Billion, - Reports Fourth-Quarter Diluted EPS of $2.26 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.31, an Increase of 13.4 Percent, - Delivers Fourth-Quarter Net Revenues of $14.886 Billion, an Increase of 7.4 Percent on a GAAP Basis, - Provides 2022 GAAP Diluted EPS Guidance Range of $9.26 to $9.46; Provides 2022 Adjusted Diluted EPS Guidance Range of $14.00 to $14.20. The safety results in this study were consistent with the known profile of Rinvoq, with no new safety risks observed. AbbVie is the sole U.S. manufacturer of Humira, an injectable biologic agent approved to treat inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and Crohn's disease. AbbVie announced the FDA approved Skyrizi for the treatment of adults with active PsA. At the 2021 American Headache Society (AHS) Annual Scientific Meeting, AbbVie presented a total of 23 abstracts, including four podium presentations, from a broad range of studies across AbbVie's . NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. • Grew annual Humira ambassador . Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. As of January 31, 2022, AbbVie was employing some 50,000 people globally. At the American Academy of Ophthalmology Annual Meeting (AAO), AbbVie presented new data from its leading eye care portfolio. Annual sales responsibility totaling $7.5 million. AbbVie Inc. (NYSE:ABBV) went down by -0.70% from its latest closing price compared to the recent 1-year high of $175.91. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.32 to $12.52 to $12.37 to $12.57. The adjusted R&D expense was 12.1 percent of net revenues, reflecting funding actions supporting all stages of our pipeline. 3. Dividend Yield. On a GAAP basis, selling, general and administrative expense was 21.8 percent of net revenues. This milestone marked the second FDA-approved indication for Rinvoq. The adjusted operating margin was 51.0 percent. Mar 2020 - Aug 2021 1 year 6 months. Diluted earnings per share attributable to AbbVie Inc. Weighted-average diluted shares outstanding. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information. Acquired IPR&D represents initial costs to acquire rights to in-process R&D projects through R&D collaborations, licensing arrangements or other asset acquisitions. Annual Report 2021 > Researchers Areas of Focus Our research in Immunology In the pipeline Our R&D team Researcher bios Research Publications . Jan 2014 - Sep 20217 years 9 months. Allergan Aesthetics announced the launch of SkinMedica Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and décolleté area. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information.

Grille Salaire Praticien Hospitalier Contractuel 2020,